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ABSTRACT

Tuberous sclerosis complex (TSC) is an inherited genetic disorder caused by loss-offunction mutations in either TSC1 or TSC2. Their respective gene products regulate the
mechanistic target of rapamycin (mTOR) signaling pathway, which serves as an activator
of cellular proliferation, metabolism, and cell survival. Orthologs of the TSC1 and TSC2
genes exist in a wide range of organisms, including the commonly used and genetically
tractable model eukaryote, Schizosaccharomyces pombe. To better understand the
functional roles of S. pombe tsc1 and tsc2, I exploited recent advances in genetic interaction
biology to identify and characterize genes that modulate the phenotypic effects of tsc1 and
tsc2 gene deletions. As part of this work, I found ypa1 (encoding a peptidyl-prolyl cis-trans
isomerase) and fft3 (encoding an ATP-dependent DNA helicase) to be negatively
interacting with both tsc1 and tsc2. Importantly, while the loss of either ypa1 or fft3 in
isolation had negligible effects on colony growth, their loss in tsc1Δ or tsc2Δ backgrounds
resulted in significant growth impediments. Thus, the inhibition of either ypa1 or fft3 might
represent an “Achilles’ heel” of cells defective in tsc1 or tsc2 function. Lastly, I found that
the negative interaction between ypa1 and tsc2 is conserved in mammalian cells. This
suggests that the targeted inhibition of the orthologous gene product in humans epitomizes
a novel therapeutic strategy to combat the TSC pathology.

Keywords: tuberous sclerosis complex, fission yeast, gene buffering, genetic interaction,
synthetic growth defect, mTOR pathway
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CHAPTER I: INTRODUCTION

1.1 Tuberous sclerosis complex
Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder with an
occurrence of approximately 1 in 8,000 live births (Rosner et al., 2004; Rosser et al., 2006).
The disease causes benign tumors (known as hamartomas) in the brain, heart, kidneys,
lungs, and eyes (Napolioni and Curatolo, 2008; Roux et al., 2004). Moreover, patients often
suffer from a variety of skin conditions (e.g. hypomelanotic macules, facial angiofibromas,
and forehead plaques) (Rosner et al., 2008). Neurological conditions such as autism,
seizures, and learning disabilities are also common among affected individuals (Sampson,
2009; Young and Povey, 1998). Figure 1-1 outlines the major clinical manifestations of
the TSC pathology.
Loss of heterozygosity in either TSC1 gene or the TSC2 gene is frequently
associated with the TSC pathology in humans (Hengstschlӓger et al., 2001; Jones et al.,
1999). The TSC1 gene on chromosome 9q34 encodes hamartin, a 130-kDa hydrophilic
protein containing a transmembrane domain and a coiled-coil domain that mediates
protein-protein interactions (van Slegtenhorst et al., 1997; Jozwiak, 2006). The TSC2 gene
on chromosome 16p13.3 encodes tuberin (The European Chromosome 16 Tuberous
Sclerosis Consortium, 1993). Tuberin, a protein of approximately 200 kDa, forms an
intracellular heterodimeric complex with hamartin to regulate downstream signaling
(Jozwiak, 2006; Rosner et al., 2004). This process is regulated by tuberin phosphorylation
which prevents both the degradation of tuberin by ubiquitination and the formation of
homomeric hamartin complexes (Laplante and Sabatini, 2006; Rosner et al., 2004).
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Figure 1-1: The multisystem pathogenesis of tuberous sclerosis complex. A range
of tissues and organs are affected in those with TSC. Respective clinical conditions are
noted in the blue boxes with percentages representing the corresponding occurrence in
patients. Red stars (*) indicate clinical conditions that may arise from alternate TSCRheb signaling networks. Reproduced from Neuman and Henske (2011) under the fair
use provision of the Canadian Copyright Modernization Act (2012).
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The hamartin-tuberin heterodimer is a key upstream component of the mechanistic
target of rapamycin (mTOR) signaling pathway (Laplante and Sabatini, 2006).
Importantly, homologs of the human TSC1 and TSC2 proteins are found across a range
species, demonstrating that the signaling network is highly conserved (Figure 1-2)
(Serfontein et al., 2011). Studies have also shown that the TSC1-TSC2 heterodimer act as
a tumor suppressing complex to regulate cellular growth and proliferation (Mak and
Yeung, 2004; Piedimonte et al., 2006; Roux et al., 2004). Interestingly, TSC-specific tumor
progression follows the Knudson two-hit model of oncogenesis (i.e. where an inherited
loss of function mutation in one allele and a sporadic loss of function mutation in the
remaining allele lead to loss of heterozygosity at either the TSC1 or TSC2 locus) (Jozwiak
et al., 2008; Mak and Yeung, 2004).

1.2 The Akt-TSC1/2-mTOR signaling pathway
The mTOR signaling pathway plays an important role in regulating cellular growth,
proliferation, survival and metabolism (Franz and Weiss, 2012). mTOR is a
serine/threonine kinase that belongs to the phosphoinositide 3-kinase (PI3K) related kinase
family (Xu et al., 2014). mTOR is evolutionarily conserved and forms the catalytic core of
two distinct multi-protein complexes, mTOR complex 1 (mTORC1), and mTOR complex
2 (mTORC2) (Laplante and Sabatini, 2012); together, they promote cell growth in response
to positive inputs such as nutrients and growth factors (Menon et al., 2014).
The hamartin-tuberin heterodimer (TSC1-TSC2 complex) is a key upstream
regulator of mTORC1 (Laplante and Sabatini, 2012). Tuberin possesses a catalytic GTPase
activating protein (GAP) domain and works to negatively regulate the downstream Rheb

3

Figure 1-2: The conservation of hamartin and tuberin across species. Domain
structure of the TSC1 (hamartin) and TSC2 (tuberin) proteins across species. Various
colours indicate the relative level of homology to the orthologous human TSC proteins.
The fission yeast Tsc1p and Tsc2p proteins are indicated with a red arrow. The coiledcoil (CC) domains of the human TSC1 and TSC2, in addition to the TSC1 interaction
domain (T1-ID) and GAP domain of TSC2 are conserved in S. pombe. The TSC2
interaction domain on TSC1 (T2-ID) is not shown to be conserved, but this conclusion
is not consistent between different alignments (Serfontein et al., 2011) and studies have
shown Tsc1p-Tsc2p heterodimers exist in fission yeast (discussed later). Figure
modified from Neuman and Henske (2011) under the fair use provision of the Canadian
Copyright Modernization Act (2012).
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protein (Manning and Cantley, 2003). Rheb (Ras homolog enriched in brain) is rendered
inactive (GDP bound) by the negative GTPase activity of tuberin (Laplante and Sabatini,
2012). Once growth factors and nutrients activate the insulin receptors (IR), PI3K can
recruit phosphoinositide dependent protein kinase-1 (PDK1) which mediates serine
phosphorylation of serine/threonine kinase Akt (Xu et al., 2014). Upon activation, Akt can
phosphorylate and subsequently inhibit the TSC1-TSC2 complex; this results in the
activation of Rheb (now GTP bound), which mediates the downstream activation of
mTORC1 (Astrinidis and Henske, 2005; Benjamin and Hall, 2014; Dalle Pezze et al.,
2012). Aforementioned cell growth and proliferation is achieved upon further
phosphorylation of several downstream effectors by mTORC1, leading to activation of the
ribosomal s6 kinase-1 (p70S6K1) and inhibition of the 4E binding protein-1 (4E-BP1)
(Manning and Cantley, 2003).
Adding to the complexity of the Akt-TSC1/2-mTORC1 pathway is a negative
feedback loop, initiated by p70S6K1-dependent phosphorylation and inhibition of IRs
(Dalle Pezze et al., 2012). Furthermore, low energy levels, hypoxia, and cellular stress are
also able to inactivate mTORC1 signaling (Benjamin and Hall, 2014). Growth factors can
also modulate mTORC2 activation, however, the complex is geared towards cell survival,
metabolism, and cytoskeletal organization (Dalle Pezze et al., 2012; Laplante and Sabatini,
2012). Previous works suggest that mTORC2 activity is dependent on PI3K and is resistant
to both rapamycin and the negative feedback loop that moderates mTORC1 activity (Dalle
Pezze et al., 2012). Interestingly, mTORC2 activity is independent of Akt-TSC1/2
regulation, suggesting a different regulatory mechanism for this signaling cascade (Dalle
Pezze et al., 2012). Figure 1-3 provides a summary of the mTORC1 signaling pathway.
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Figure 1-3: The Akt-TSC1/2-mTORC1 signaling cascade. Upon stimulation of the
insulin receptors (IRs), the mTORC1 complex promotes increased levels of protein
synthesis, inhibition of autophagy, cell growth and proliferation. Upstream kinases –
PI3K and PDK1 modulate the phosphorylation and subsequent activation of Akt. Next,
pAkt inactivate the TSC1-TSC2 heterodimeric complex, leading to an activated
mTORC1. Activated mTORC1 phosphorylates and inhibits downstream 4E-BP1,
which would otherwise repress protein translation. In contrast, mTORC1-mediated
phosphorylation of S6K1 promotes ribosomal protein synthesis. The pathway is also
regulated by several feedback mechanisms (not shown).
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1.3 Fission yeast as a model system to study the TSC pathology
The fission yeast Schizosaccharomyces pombe is a unicellular organism commonly used
in the field of eukaryotic cellular and molecular biology. It is genetically tractable and is
often used to examine fundamental cellular processes such as transcription, translation,
cell-cycle control, DNA damage and repair, signaling pathways, and epigenetics (Forsburg,
2005; Hoffman et al., 2015).
The S. pombe genome has been fully sequenced to reveal ~ 5000 protein-coding
genes (ORFs) distributed among three chromosomes (Wood et al., 2002). Among the
proteins encoded by the S. pombe genome, a subset of 172 proteins share close homology
with human disease proteins (Wood et al., 2002). Moreover, the S. pombe laboratory strains
can be diploid or haploid – carrying only a single set of chromosomes (Forsburg and Rhind,
2006). This is crucial in examining genes of interest in disease models, as mutant alleles
can be screened for loss-of-function phenotypes when compared to the wild type alleles
(Hoffman et al., 2015). Altogether, the ease of manipulation and the genomic conservation
of S. pombe makes it a powerful tool to study human disease.
Orthologs of human TSC1 and TSC2 genes have been identified in fission yeast
(named tsc1 and tsc2, respectively) (Serfontein et al., 2011; Sun et al., 2013). In addition,
several components of the mTOR signaling pathway are also conserved in S. pombe
(Figure 1-4) (Aspuria et al., 2007; Wullschleger et al., 2006). Functional Tsc1p and Tsc2p
are crucial in nutrient uptake and the regulation of biosynthetic pathways (Mak and Yeung,
2004). Moreover, the fission yeast Tsc1p-Tsc2p heterodimer regulates a downstream Rheb
protein (ortholog of mammalian Rheb) through its GAP activity (Aspuria et al., 2007). As
in mammalian cells, Rheb in a GTP-bound state can then activate the S. pombe Tor proteins
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Figure 1-3: The TSC/Rheb/mTOR signaling pathway is well conserved in S.
pombe. Orthologs of human TSC1 and TSC2, along with several components of the
mTOR signaling pathway is conserved in fission yeast. TSC1 and TSC2 orthologs do
not exist in the budding yeast Saccharomyces cerevisiae. Furthermore, S. pombe Tor2p
forms a complex (with Mip1p and Wat1p) akin to the mammalian mTORC1 to regulate
cell cycle and cellular growth. The Tor2p is activated by the upstream Rheb protein
which is regulated by the GAP activity of Tsc1p-Tsc2p heterodimer. However, unlike
in mammalian cells (Akt phospohorylation of TSC1-TSC2), the upstream regulatory
mechanisms of the Tsc1p-Tsc2p complex in fission yeast remain unknown. Proteins
with the same color share substantial structural homology across species (i.e.
mammalian Raptor, fission yeast Mip1p, and budding yeast Kog1p). Reproduced from
Aspuria et al. (2007) under the fair use provision of the Canadian Copyright
Modernization Act (2012).
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(orthologs of mTOR) (Wullschleger et al., 2006). However, in S. pombe, the Tor2p forms
the TOR1 complex which interacts in a mTORC1-like manner to regulate protein
translation, metabolism and nutrient dependent cellular growth and proliferation (Gonzalez
and Rallis, 2017; Matsuo et al., 2007; Rallis et al., 2014). Nonetheless, S. pombe is a great
adjunct in examining the mechanisms of mammalian TOR signaling and, as such, is
important in the understanding of the TSC pathology.

1.4 Gene buffering and genetic interactions
Loss-of-function mutations are crucial in contrasting mutant phenotypes with their
respective wild-type phenotypes. In nature, however, these phenotypes are often
quantitative and the mechanisms underlying a disease are multifaceted (Hartman IV et al.,
2001; Horn et al., 2011). Gene buffering is a phenomena which provides robustness against
genetic mutations leading to phenotypic variation and complexity (Kitami and Nadeau,
2002). Classically, gene buffering occurs between genes within the same biological
pathway or in parallel pathways with complementary cellular functions (Hartman IV et al.,
2001). However, genes in ‘redundant’ pathways of unrelated biochemical functions can
also buffer one another (Kitami and Nadeau, 2002).
Unpredicted phenotypic outcomes resulting from gene buffering between genes are
coined as genetic interactions (Costanzo et al., 2011). Recent advances in genome-wide
synthetic genetic array (SGA) analysis have allowed for high-throughput identification of
these interactions (Collins et al., 2007; Costanzo et al., 2010). Furthermore, digenic
(between two genes) interactions can be scored by comparing the fitness of the double
mutants – typically colony growth size, against the fitness of the respective single mutants
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(Baryshnikova et al., 2010; Costanzo et al., 2011; Frost et al., 2012). A digenic genetic
interaction is categorized as being either ‘positive’ or ‘negative’ in nature (Baryshnikova
et al., 2010). Positive interactions occur when the observed double mutant fitness is greater
than expected (Costanzo et al., 2011). In contrast, negative interactions occur when double
mutant fitness is less than expected (Baryshnikova et al., 2010). Figure 1-5 summarizes the
key concepts of gene buffering.
Included in the set of negative interactions are cases of synthetic lethality/sickness
(Dixon et al., 2008). In these cases, the simultaneous loss of two gene products results in
death or severe growth defects, but the loss of either gene-product individually has little or
no effect (Baryshnikova et al., 2013; Costanzo et al., 2011). In tumor cells, synthetic
growth defects may also arise between genes and small molecules as a mode of drug
discovery; this is because, a typical tumor cell accumulates genetic mutations and
morphological changes, exposing the tumor cell to vulnerabilities that a normal cell would
not face (Nijman, 2011). Thus, protein products of genes that are synthetic lethal to tumorforming genetic mutations are ideal candidates for therapeutic targets (Kaelin, 2005).
Hartwell et al. (1997) forged this concept of selectively targeting tumor cells to uncover
prospective anticancer drugs. The group used yeast gene deletion mutants to screen
pharmaceutical inhibitors (Kaelin, 2005). However, technological advances in gene
knockdowns using short interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs),
and CRISPR/Cas9-mediated complete gene knockouts through guide RNAs (gRNAs) have
made it possible to lead high-throughput screens for synthetic lethality across genomes
(Beijersbergen et al., 2017). Figure 1-6 highlights the fundamental strategies used with
respect to the exploitation of synthetic lethality in uncovering novel cancer therapeutics.
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Figure 1-5: The buffering of genetic variation. (A) Phenotypic variation due to gene
A is modulated by gene B, and vice versa. The dotted circle (upper panel) highlights the
capacity of gene A to “buffer” variation in gene B. This is to say, in the presence of
functional gene A, gene B can accumulate genetic variation without affecting its activity
(lower panel). Simultaneous mutations in both genes A and B lead to an abrogation of
genetic buffering and a lethal phenotype (red arrow). Modified from Hartman IV et al.
(2001) under the fair use provision of the Canadian Copyright Modernization Act (2012).
(B) Negative genetic interactions arise when the double mutant (AB) fitness/phenotype
is impaired beyond the expected. The resultant synthetic growth defect can be classified
as synthetic sick or synthetic lethal. Modified from Costanzo et al. (2011) under the fair
use provision of the Canadian Copyright Modernization Act (2012).

11

Figure 1-6: Applying synthetic lethality to cancer therapeutics. (A) Standalone
mutations to either gene A or gene B is tolerated (viable phenotype). However,
simultaneous mutation of both genes causes lethality. Reproduced from Kaelin W
(2005) under the fair use provision of the Canadian Copyright Modernization Act
(2012). (B) The tumor cells have acquired a genetic mutation in gene A. Since gene A
and B are synthetic lethal, inhibition of gene B or the gene B protein product with an
Anti-B agent (gene knockout or pharmacological inhibitor) will lead to tumor-specific
cell death. Awt = wild-type gene A, and Am = mutant gene A. Reproduced from
Beijerbergen et al. (2016) under the fair use provision of the Canadian Copyright
Modernization Act (2012).
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Fortunately, these strategies have led to the discovery of numerous drug targets across a
variety of cancer models (Beijersbergen et al., 2017; Costa-Cabral et al., 2016; Pourdehnad
et al., 2013).

1.5 Genetics to therapeutics: rationale for my study
Inhibition of mTOR signaling with rapamycin has previously shown therapeutic benefits
in treating TSC patients; but, rapamycin-independent pathways are also thought to play a
role in the manifestation of the disorder (Franz and Weiss, 2012; Kenerson et al., 2005).
Furthermore, resistance to rapamycin treatment has been observed in rat models of the
disease (Kenerson et al., 2005; Mak and Yeung 2004). Interestingly, combination therapies
involving rapamycin and secondary drugs have shown potency in limiting tumorigenesis
(Li et al., 2007; Perera et al., 2009). Hence, the identification of alternate ‘drugable’ targets
for novel and/or combination therapies may provide more effective options for the
treatment of the TSC pathology (Neuman and Henske, 2011).
Fortunately, recent advances with respect to genetic buffering have provided novel
avenues of therapeutic exploration. These avenues rely on the creation of genetic
interaction maps, known as genetic interactomes (Costanzo et al., 2011). Genome-wide
interactomes and subsequent analyses in budding yeast, Caenorhabditis elegans, and
mouse fibroblasts, have shown that these interactions can influence a variety of phenotypes
associated with complex genetic phenomenon, including human disorders (Baryshnikova
et al., 2013). Of particular interest to TSC researchers are negative interactor genes that
display synthetic growth defect in conjunction with the TSC1 or TSC2 loss of
heterozygosity. Inhibiting such genes would presumably impede the growth of
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homozygous tumor cells (bearing two mutant copies of the affected TSC gene) while
leaving phenotypically normal heterozygous cells unaffected (carrying only the mutant
germline copy) (Beijersbergen et al., 2017; Kaelin, 2005). Interestingly, a recent screen for
synthetic growth defects in mammalian cells led to the identification of candidate drug
targets for the TSC pathology (Housden et al., 2015). Therefore, these negative interactors
might represent an “Achilles’ heel” of tumor cells deficient in hamartin/tuberin function
and, therefore, are ideal targets for therapeutic intervention in TSC patients.
Ryan et al. (2012) recently constructed a large-scale genetic interactome for the
fission yeast S. pombe. The group has provided an opportunity to test the idea that genetic
buffering relationships can indeed be exploited to identify novel drug targets. Using the
genetically tractable fission yeast as a model, my study aimed to utilize advances in genetic
interaction biology to elucidate the cellular and molecular mechanisms of TSC
pathogenesis. In brief, a series of experiments were conducted to address the following
areas of interest: (i) the validation of putative negative interactors of fission yeast tsc1 and
tsc2, (ii) the identification of sites within these interactors that may be amenable to
pharmacological inhibition, (iii) investigation of the fission yeast tsc2 alleles bearing
orthologous mutations to clinical TSC patients, and (iv) the conservation of S. pombe
synthetic interactions in mammalian cells. Altogether, my study sought to identify novel
targets for inhibitory drugs, to be used alone (or in combination with rapamycin) to obstruct
tumor-specific growth in individuals affected by the TSC pathology.
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1.6 Hypothesis and predictions
I hypothesize that perturbation of the fission yeast negative interactor genes will alter the
cellular growth of the tsc1Δ and tsc2Δ mutants as well as the tsc2 strains bearing
orthologous clinical mutations (i.e. loss of function mutations). Additionally, I predict that
complete gene deletions of the validated interactors, or the site-directed mutagenesis within
their catalytic sites will result in the impediment of colony growth in tsc1Δ and tsc2Δ
mutant backgrounds. In contrast, I predict that the effect of the mutated interactors in
fission yeast cells lacking loss of function mutations of tsc1 and tsc2 will be negligible.
Moreover, I hypothesize that the synthetic interactions in S. pombe will be
conserved in mammalian cells. I predict that RNAi-mediated knockdowns of target genes
(orthologous to the validated fission yeast negative interactors) in TSC2-deficient mouse
fibroblasts will result in cell-specific lethality. I expect such treatments to reduce cellular
viability in fibroblasts that match the molecular context of the TSC tumor cells.
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CHAPTER II: MATERIALS AND METHODS

2.1 Yeast strains and culture conditions
Fission yeast strains were cultured as indicated in YES, SPA, or EMM media supplemented
with a combination of adenine, histidine, leucine, and uracil (Forsburg and Rhind, 2006).
Gene deletion strains used in the study were obtained from Bioneer Corporation
(https://us.bioneer.com/products/spombe/Library-overview.aspx).

Bioneer

employs

homologous recombination (HR) to replace an ORF of interest with a deletion cassette
(Kim et al., 2010). The deletion cassettes are comprised of a kanMX4 selection marker,
which confers resistance to the antibiotic, G418, along with flanking tag sequences and
two fragments homologous to the 5’ and 3’ flanking region of the target ORF (Figure 2-1).
Several S. pombe strains bearing site-directed mutations were also constructed. The
relevant DNA sequences bearing the desired mutations were synthesized by GenScript®
and cloned into the S. pombe integration vector, pJK210. The integration constructs were
linearized and then transformed into a wild-type strain using the lithium acetate protocol
(Gietz et al., 1992). Viable colonies in uracil-deprived EMM-agar media were assessed for
integration at the desired locus through colony PCR (Figure 2-2). The products of the
colony PCR reactions were analyzed on 1% agarose gels made with tris-acetic EDTA
(TAE) buffer and stained with RedSafe™ solution (iNtRON Biotechnology). The
genotypes of all S. pombe strains used in this study are listed in Table 2-1.
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Figure 2-1: Methodology used to construct the Bioneer haploid gene deletion
mutant set. Deletion cassettes bearing i) the kanMX4 marker, ii) flanking tag
sequences, and iii) sites of homology to the fission yeast gene of interest were integrated
into wild-type S. pombe cells via homologous recombination (Kim et al., 2010).
Colonies bearing the construct were selected on YES-agar plates supplemented with
G418.
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Figure 2-2: Methodology used to generate ypa1 and fft3 mutant strains via sitedirected mutagenesis. The relevant mutant DNA sequences (e.g. to generate the fft3K418R mutant) were designed and ordered from GenScript®. The synthesized
sequences arrived cloned into the pUC57 vector. (1) The mutant sequence is freed from
the pUC57 vector by restriction digestion (digestion site indicated by vertical grey
lines). (2) The restriction fragment is cloned into the S. pombe integrating vector
pJK210 via enzymatic ligation. (3) The vector is linearized via restriction digestion
(digestion site indicated by a vertical grey line). (4, 5) The linearized vector is
transformed into S. pombe where it integrates at the native locus via homologous
recombination to generate mutant colonies on uracil-deprived EMM media. (6, 7)
Integration at the correct locus is verified by colony PCR (2678 bp amplification).
Vertical red bars represent the site-directed mutation of Lysine418 (K418R). Bright teal
arrows indicate the primer set used to verify fft3-K418R integration into the wild-type
fission yeast genome.
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Table 2-1. S. pombe strains used in the study.
Strain

Genotype

Source

JK484

ura4-D18 leu1-32 ade6-210 his3-D1 h-

JK collection

ED666

ura4-D18 leu1-32 ade6-210 h+

JK collection

UC7

ura4-D18 h+

JK collection

UC8

ura4-D18 h-

JK collection

TSC13

tsc1::ura4 ura4-D18 h+

Bioneer

TSC14

tsc2::ura4 ura4-D18 h+

Bioneer

TSC17

tsc1::ura4 ura4-D18 h-

JK collection

TSC18

tsc2::ura4 ura4-D18 h-

JK collection

TSC83

ypa1::kanMX4 h+

Bioneer

TSC86

fft3::kanMX4 h+

Bioneer

P17-81

cdk11::kanMX4 h+

Bioneer

AR1

ypa1-D212G::ura4+

This study

AR2

ypa1-V208D::ura4+

This study

AR3

fft3∆791-872::ura4+

This study

AR4

fft3-K418R::ura4+

This study

TSC154

tsc2::tsc2-R1296P h-

JK collection

NGE1

lip2::kanMX4 h+

Bioneer

NGE2

aap1::kanMX4 h+

Bioneer

NGE3

atg14::kanMX4 h+

Bioneer

NGE4

spac25a8.03c::kanMX4 h+

Bioneer
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2.2 Generation of S. pombe double mutants
Fission yeast double mutants were generated using standard genetic techniques (Forsburg
and Rhind, 2006). Briefly, cells of each single mutant strain were mixed on SPA-agar
media and incubated at 30°C as mating process is temperature-sensitive. SPA media is
nitrogen-deprived and induces mating and sporulation, resulting in tetrads, each comprised
of four haploid spores. Once a given cross was plated on a fresh YES-agar plate, a Zeiss
Axioskop 40 microscope was utilized to dissect the individual tetrad. Following a brief
incubation period at 30°C (to break down tetrad walls), the haploid spores were separated.
The individual spores formed colonies within 48 hours and viable double mutants were
isolated on YES-agar plates containing G418 antibiotic and/or EMM media lacking uracil.

2.3 Colony growth analysis
The S. pombe double mutant strains were streaked onto YES-agar plates along with the
respective single gene deletion mutants and a wild-type control. Next, the Zeiss Axioskop
40 microscope was utilized to separate individual cells and arrange them across the YESagar media (three trials consisting a maximum of four technical replicates from each
strain). The plates were incubated at 30°C for five days to assay colony growth. Images
were taken every 24 hours using an Alpha Innotech Flurochem SP imaging system. Colony
sizes were measured using ImageJ (Abràmoff et al., 2004).

2.4 Cell culture and reagents
Tsc2+/+p53-/- (P118) and Tsc2-/-p53-/- (P119) mouse embryonic fibroblasts (MEFs) were
kindly provided by Dr. DJ Kwiatkowski, Brigham and Women’s Hospital, Harvard
21

Medical School, Boston, MA, USA. These MEFs are connective tissue cells that are
precursors to extracellular matrix and collagen, harvested from mouse embryos age
embryonic day10.5 (E10.5) (Zhang et al., 2003). The p53 knockout (p53-/-) was necessary
to prevent premature senescence of the Tsc2-/- MEFs (Zhang et al., 2003). All cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10%
fetal bovine serum (FBS), 100 IU/mL penicillin, and 100 µg/mL streptomycin (pen-strep).
The cells were grown at 37°C in a humidified atmosphere of 5% CO2 and 95% air up to
70-90% confluency before sub-culturing. P118 and P119 cell cultures were observed and
imaged using an inverted Leica DM IL LED microscope in integrated modulation contrast
(IMC) mode. DMEM and FBS were purchased from Life Technologies. Pen-strep, DPBS,
and TrypLE were obtained from Gibco. Trypan Blue for cell counting was purchased from
Sigma-Aldrich. Falcon T-25 and T-75 animal cell culture flasks were used to passage and
maintain the MEFs.

2.5 Genotyping the mouse embryonic fibroblasts
The Tsc2-/- line was previously generated by inserting a neomycin cassette into exon 3 of
the Tsc2 gene (Figure 2-3) (Onda et al., 1999). To confirm the knockout, genomic DNA
(gDNA) was isolated from the P118 and P119 MEFs using DNAzol® (Molecular Research
Centre, Inc.). Subsequent PCR reactions were performed using oligonucleotides H162,
H163, and H164 (Table 2.2). PCR products were analyzed on 1.7% agarose gel made with
TAE buffer and stained with SYBR® safe (Invitrogen).
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Figure 2-3: Generation of the Tsc2-/- allele in mouse embryonic fibroblasts. A
neomycin cassette was inserted into exon 3 of the mouse Tsc2 gene (Onda et al., 1999).
This construct disrupted Tsc2 coding sequence (CDS). Coloured arrows represent the
primer binding sites of the oligonucleotides designed to confirm the absence/presence
of the neomycin cassette in the P118 and P119 MEFs.
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2.6 Transfections
siGENOME SMARTpool siRNAs targeting Ppp2r4 and Smarcad1 mouse genes were
purchased from Dharmacon™. In addition, a scrambled siRNA targeting no known mouse
gene was also obtained. A working concentration of 10 nM was used for each siRNA for
transfections. All transfections were done using the Lipofectamine® RNAiMAX
transfection reagent (Invitrogen) according to the manufacturer’s protocol. Cells were
grown to 40-60% confluency in media lacking pen-strep. Transfections were then
performed in either 24-well or 96-well plates. Cells were then incubated at 37°C with 5%
CO2 for 48 hours before further assays were performed.

2.7 RNA extraction and cDNA synthesis
Cells were transfected with siRNAs in 24-well plates and incubated for 48 hours. Total
RNA was then isolated from transfected cells using TRIzol™ Reagent (Invitrogen)
according to the manufacturer’s protocol. SuperScript™ III First-Strand Synthesis
Supermix for qRT-PCR kit (Invitrogen) was used to generate respective cDNA from 1 µg
of total RNA. Subsequent PCR reactions were performed with AR3F and AR3R, AR4F
and AR4R, or AR5F and AR5R to confirm gene knockdowns (Table 2-2). PCR products
were then analyzed on 1.7% agarose gel made with TAE buffer and stained with SYBR®
Safe (Invitrogen).
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Table 2-2. Oligonucleotides used in the study. Complete forward (F) and reverse (R)
primer sequences along with the size of the PCR products are shown.

Primers
AR1

Gene
ypa1

Sequence (5’ to 3’)
F: TACAGCGTCTCAATATTGCATCTG

Amplicon Size
1024 bp

R: TCCTATGTTGTGTGGAATTGTGAG
AR2

AR3

fft3

Gapdh

F: TCCCTCATTTACTTCCTCTGCTAA
R: TCCTATGTTGTGTGGAATTGTGAG

2426 bp (fft3∆791872) and 2678 bp
(fft3-K418R)

F: TGGCCTTCCGTGTTCCTAC

178 bp

R: GAGTTGCTGTTGAAGTCGCA
AR4

Ppp2r4

F: ACCCCTCCAACTACTCAGAAC

215 bp

R: CACCTATCCAGCGTATCAAGAAG
AR5

Smarcad1 F: TGTTTGCGGAAGATCAAGACG

201 bp

R: CAGAGTCCTCTACGGCTTTCTTA
H162/
H163

Tsc2

F: ACCCACCTCCTCAAGCTTCT

198 bp

R: AGACTGCCTTGGGAAAAGCG
H162/
H164

Tsc2

F: ACCCACCTCCTCAAGCTTCT
R: TTGGTTTACAGGGGAAATGC
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96 bp

2.8 Cell viability assay
The viability of siRNA-transfected cells was evaluated using the CellTiter-Glo®
Luminescent Cell Viability Assay (Promega). The assay mobilizes ATP in the viable cells
to emit stable luminescent signals that can be measured. The results from the assay
estimates metabolically active cells and can be analyzed to determine differences in cell
viability among various groups. P118 and P119 MEFs were first seeded at 0.25 x 106
cells/mL in 96-well plates (100 µL/well). Cells were then transfected with the relevant
siRNAs within a 24 hours incubation period. After a transfection period of 48 hours, 100
µL of the CellTiter-Glo reagent was directly added to the individual wells. The Infinite
M1000 (Tecan) monochromator based microplate reader was utilized to quantify the
“glow-type” luminescent signals in the 96-well plates.

2.9 Data analysis
Pairwise comparisons of colony sizes were performed among the wild-type, single mutant
and the double mutant S. pombe strains. Statistically significant differences were
determined by the non-parametric Wilcoxon Rank Sum test in R v3.2.2 after applying the
Benjamini and Hochberg multiple-testing correction (Benjamini and Hochberg, 1995).
Statistically significant differences between control and siRNA treatment groups in
cell viability assays were determined by the non-parametric Friedman test in GraphPad
Prism v7.0.2 adjusted with the Benjamini and Hochberg multiple-testing correction
(Benjamini and Hochberg, 1995). Graphical illustrations were produced using the
GraphPad Prism v7.0.2 software.
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CHAPTER III: RESULTS

3.1 Validation of candidate negative interactors
Recent high-throughput efforts in S. pombe have resulted in the creation of a genetic
interaction map (http://interactome-cmp.ucsf.edu/pombe2012/modules/search.html; Ryan
et al., 2012). Analysis of this publicly available database revealed a subset of thirteen genes
that are negative interactors of both tsc1 and tsc2. This small group of genes displayed
strong synthetic growth defects (SGA scores of less than -4) when deleted in combination
with tsc1 or tsc2 gene deletions. Of these genes, only ypa1 and fft3 were selected for
validation and detailed analysis as they have clear orthologs in a variety of developmentally
complex eukaryotes, including humans (Costelloe et al., 2012; De Virgilio and Loewith,
2006; Durand-Dubief et al., 2012; Goyal and Simanis, 2012; Neves-Costa et al., 2009).
Interestingly, a genome wide screen in Drosophila spp. also identified the Pitslre gene as
a negative interactor of the fruit fly genes – Tsc1 and Tsc2 (Housden et al., 2015). As this
gene is conserved in humans (known as CDK11) as well as fission yeast (known as cdk11),
it was also included in this study.
Crosses of ypa1∆, fft3∆, and cdk11∆ mutants with either tsc1∆ or tsc2∆ S. pombe
strains were performed to generate the respective double mutants. Colony growth analysis
was then performed to monitor the growth of individual yeast cells over a period of five
days (see Figure 3-1, for an example of ypa1 mutants). Comparisons were made among
cells from the following groups – wild-type S. pombe, single gene deletion mutants, and
the corresponding double mutants.

27

Figure 3-1: Representative example of YES-agar media plate used in colony
growth analysis. Several S. pombe strains were plated in an YES-agar media plate.
Growth was monitored for 5 days. Images were taken at every 24 hours interval. Red
box highlights the tsc1∆ypa1∆ double mutant that exhibits severe growth defect
compared to the respective single mutant strains – wild type, tsc1∆, and ypa1∆.
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The colony growth analysis revealed that ypa1∆ demonstrated strong synthetic
growth defects with both tsc1∆ and tsc2∆ mutants (Figure 3-2). Although, both tsc1∆ and
ypa1∆ single mutant strains were hindered in their ability to grow, the tsc1∆ypa1∆ double
mutant colony sizes were significantly perturbed (p < 0.0005 at day 5, for all pairwise
comparisons with double mutants; Figure 3-2B). The tsc2∆ypa1∆ double mutants also
followed a similar trend of growth impediment (p < 0.0005 at day 5, for all pairwise
comparisons with double mutants; Figure 3-2D). In addition, fft3∆ mutant demonstrated
strong negative interaction with both tsc1∆ and tsc2∆ mutants (p < 0.0005 at day 5, for all
pairwise comparisons with double mutants; Figure 3-3 B, D). The resultant colony growth
defects of the double mutants (tsc1∆fft3∆ and tsc2∆fft3∆) followed similar growth pattern
to that of the tsc1∆ypa1∆ and tsc2∆ypa1∆ double mutants (Figures 3-2 A, C & 3-3 A, C).
In contrast, the cdk11 gene deletion mutants did not exhibit any clear growth
impediment. The tsc1∆cdk11∆ and tsc2∆cdk11∆ double mutant colonies were significantly
smaller than the wild-type colonies (p < 0.0005 at day 5, for all pairwise comparisons with
double mutants; Figure 3-4 B, D). However, the double mutant colonies demonstrated
similar growth to tsc1∆, tsc2∆, and cdk11∆ single mutants (p > 0.05 at day 5, for all
pairwise comparisons with double mutants; Figure 3-4 A, C). Altogether, ypa1 and fft3
were confirmed as negative interactors of both tsc1 and tsc2. As such, the two fission yeast
genes were carried forward for further detailed analysis.

3.2 Additional synthetic interaction screens
Recent work in S. cerevisiae has indicated that negative interactions can be falsely
annotated due to neighboring gene effects (NGEs); whereby, the deletion of a gene can
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Figure 3-2: tsc1∆ypa1∆ and tsc2∆ypa1∆ double mutants exhibit reduced colony
growth relative to the respective single mutants. (A) Heat map describing average
colony size (arbitrary units) in wild-type, tsc1Δ, ypa1Δ, and tsc1Δypa1Δ mutants over
five days (n = 12, for all groups). (B) Box and whisker plot describing average colony
size (arbitrary units) in wild-type, tsc1Δ, ypa1Δ, and tsc1Δypa1Δ mutants at day 5. (C)
Heat map describing average colony size (arbitrary units) in wild-type, tsc2Δ, ypa1Δ,
and tsc2Δypa1Δ mutants over five days (n = 12, for all groups). (D) Box and whisker
plot describing average colony size (arbitrary units) in wild-type, tsc2Δ, ypa1Δ, and
tsc2Δypa1Δ mutants at day 5. Lower case letters represent significant differences (if
any) among the groups.
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Figure 3-3: tsc1∆fft3∆ and tsc2∆fft3∆ double mutants display decreased colony
growth relative to the respective single mutants. (A) Heat map describing average
colony size (arbitrary units) in wild-type, tsc1Δ, fft3Δ, and tsc1Δfft3Δ mutants over five
days (n = 12, for all groups). (B) Box and whisker plot describing average colony size
(arbitrary units) in wild-type, tsc1Δ, fft3Δ, and tsc1Δfft3Δ mutants at day 5. (C) Heat
map describing average colony size (arbitrary units) in wild-type, tsc2Δ, fft3Δ, and
tsc2Δfft3Δ mutants over five days (n = 12, for all groups). (D) Box and whisker plot
describing average colony size (arbitrary units) in wild-type, tsc2Δ, fft3Δ, and tsc2Δfft3Δ
mutants at day 5. Lower case letters represent significant differences (if any) among the
groups.
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Figure 3-4: tsc1∆cdk11∆ and tsc21∆cdk11∆ double mutants do not exhibit differences in
colony growth relative to the respective single mutants. (A) Heat map describing average
colony size (arbitrary units) in wild-type, tsc1Δ, cdk11Δ, and tsc1Δcdk11Δ mutants over five
days (n = 11, 12, 12, and 12, respectively). (B) Box and whisker plot describing average colony
size (arbitrary units) in wild-type, tsc1Δ, cdk11Δ, and tsc1Δcdk11Δ mutants at day 5. (C) Heat
map describing average colony size (arbitrary units) in wild-type, tsc2Δ, cdk11Δ, and
tsc2Δcdk11Δ mutants over five days (n = 12, for all groups). (D) Box and whisker plot
describing average colony size (arbitrary units) in wild-type, tsc2Δ, cdk11Δ, and tsc2Δypa1Δ
mutants at day 5. Lower case letters represent significant differences (if any) among the groups.
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affect the adjacent genes along a genome leading to improper annotation of negative
interactions (Atias et al., 2015). In fact, NGE is relatively extensive with a ~10% rate,
which can distort large-scale genetic interactomes (Ben-Shitrit et al., 2012). As such,
inappropriate recordings of genetic interactions require correction and subsequent
replacement with new and correct mapping of the relevant interactions. I examined
potential NGE effects on the observed data using the following mutants – lip2∆, aap1∆,
atg14∆, and spac25a8.03c∆. These genes are immediately adjacent to the previously
validated tsc1 and tsc2 negative interactors, ypa1 and fft3. The data demonstrated that the
corresponding double mutants of the adjacent gene deletion mutants do not exhibit any
significant growth defects compared to the single mutants (p > 0.05 at day 5, for all pairwise
comparisons with double mutants; Figure 3-5 & 3-6). These results provide strong evidence
that the synthetic interactions mapped in this study are not influenced by NGEs.

3.3 Identification of catalytic sites within the interactors
The determination of specific functional domains within Ypa1p and Fft3p can help identify
sites that may be amenable to pharmacological inhibitors. Based on current literature and
bioinformatic analyses, three domains were identified – one within the Ypa1p (PPIase
domain) (Jordens et al., 2006; Jouvet et al., 2011; Leulliot et al., 2006), and two within the
Fft3p (ATPase domain and helicase domain) (Byeon et al., 2013; Chen et al., 2012; Eapen
et al., 2012; Steglich et al., 2015). An online based multi-alignment tool, Clustal Omega
(Sievers et al., 2011), was used to verify the conservation of these putative sites across
several eukaryotes (Figure 3-7). Using this information, several integration constructs were
designed to create S. pombe strains expressing ypa1-D212G, ypa1-V208D, fft3-K418R, and
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Figure 3-5: Double mutants of lip2∆ and aap1∆ (adjacent to ypa1) do not exhibit
colony growth defects relative to the respective single mutants. (A, C) Heat map
describing average colony size (arbitrary units) in wild-type, tsc1Δ, tsc2Δ, lip2Δ,
tsc1Δlip2Δ, and tsc2Δlip2Δ mutants over five days (n = 12, 11, 12, 12, 11, and 11,
respectively). (B, D) Box and whisker plot describing average colony size (arbitrary
units) in wild-type, tsc1Δ, tsc2Δ, lip2Δ, tsc1Δlip2Δ, and tsc2Δlip2Δ mutants at day 5.
(E, G) Heat map describing average colony size (arbitrary units) in wild-type, tsc1Δ,
tsc2Δ, aap1Δ, tsc1Δaap1Δ, and tsc2Δaap1Δ mutants over five days (n = 12, 12, 12, 12,
10, and 12, respectively). (F, H) Box and whisker plot describing average colony size
(arbitrary units) in wild-type, tsc1Δ, tsc2Δ, aap1Δ, tsc1Δaap1Δ, and tsc2Δaap1Δ
mutants at day 5. Lower case letters represent significant differences (if any) among the
groups.
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Figure 3-6: Double mutants of atg14∆ and spac25a8.03c∆ (adjacent to fft3) do not
exhibit colony growth defects relative to the respective single mutants. (A, C) Heat
map describing average colony size (arbitrary units) in wild-type, tsc1Δ, tsc2Δ, atg14Δ,
tsc1Δatg14Δ, and tsc2Δatg14Δ mutants over five days (n = 12, 11, 12, 11, 8, and 11,
respectively). (B, D) Box and whisker plot describing average colony size (arbitrary
units) in wild-type, tsc1Δ, tsc2Δ, atg14Δ, tsc1Δatg14Δ, and tsc2Δatg14Δ mutants at day
5. (E, G) Heat map describing average colony size (arbitrary units) in wild-type, tsc1Δ,
tsc2Δ, spac25a8.03cΔ, tsc1Δspac25a8.03cΔ, and tsc2Δspac25a8.03cΔ mutants over
five days (n = 12, 11, 12, 11, 12, and 12, respectively). (F, H) Box and whisker plot
describing average colony size (arbitrary units) in wild-type, tsc1Δ, tsc2Δ,
spac25a8.03cΔ, tsc1Δspac25a8.03cΔ, and tsc2Δ spac25a8.03cΔ mutants at day 5.
Lower case letters represent significant differences (if any) among the groups.
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Figure 3-7: Multiple sequence alignments comparing Ypa1p and Fft3p to their
human and mouse orthologs. A Highly conserved PPIase domain is present within
Ypa1p (purple box). The Fft3p contains a highly conserved ATPase domain (purple
arrow) and a helicase domain (*not shown). The pink letter boxes denote the sitedirected mutagenesis of fission yeast strains performed in this study. Sp,
Schizosaccharomyces pombe; Mm, Mus musculus; Hs, Homo sapiens.
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fft3Δ791-874 (see Materials and Methods). The mutant strains were then crossed to either
tsc1∆ or tsc2∆ strains to generate the respective double mutants.
The ypa1 site-directed double mutants (tsc1∆ypa1-D212G, tsc2∆ypa1-D212G,
tsc1∆ypa1-V208D, and tsc2∆ypa1-V208D) did not show any significant differences in
colony growth compared to their respective tsc1∆ and tsc2∆ mutant strains (p > 0.05 for
all pairwise comparisons at day 5; Figure 3-8 & Figure 3-9). Likewise, the helicase-deleted
fft3 double mutants also followed the growth trends of the tsc1∆ and tsc2∆ mutants (p >
0.05 for the pairwise comparisons at day 5; Figure 3-10). In contrast, fft3-K418R double
mutants did show a significant impediment in colony growth compared to the wild-type
and respective single mutant strains (p < 0.05 for all pairwise comparisons at day 5; Figure
3-11). However, the synthetic growth defects witnessed in these double mutants were not
as prominent as the growth defects previously seen in the fft3∆ double mutants.
Nonetheless, the result suggest that the ATPase domain within the Fft3p may be
pharmacologically targeted in cells with loss of function mutations in tsc1 and tsc2.

3.4 Assaying clinically orthologous mutations in S. pombe
As part of an ongoing project in the lab, strains expressing tsc2 alleles bearing mutations
orthologous to those found clinically have been created (G296E, R927W, N1191K,
N1199S, P1223L, R1296P) (Figure 3-12). These tsc2 alleles were examined to screen any
negative interactions with fft3 and ypa1. Of the six mentioned tsc2 mutants, only tsc2R1296P mutants were found to negatively interact with both ypa1 and fft3 (p < 0.05 for all
double mutant pairwise comparisons at day 5; Figure 3-13 A to D; data not shown for the
other five mutants). Furthermore, the growth defects exhibited by the tsc2-R1296P ypa1∆
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Figure 3-8: tsc1∆ypa1-D212G and tsc2∆ypa1-D212G double mutants do not exhibit
reduced colony growth relative to the respective single mutants. (A) Heat map
describing average colony size (arbitrary units) in wild-type, tsc1Δ, ypa1-D212G, and
tsc1Δypa1-D212G mutants over five days (n = 12, 12, 11, and 12, respectively). (B)
Box and whisker plot describing average colony size (arbitrary units) in wild-type,
tsc1Δ, ypa1-D212G, and tsc1Δypa1-D212G mutants at day 5. (C) Heat map describing
average colony size (arbitrary units) in wild-type, tsc2Δ, ypa1-D212G, and tsc2Δypa1D212G mutants over five days (n = 12, 12, 12, and 11, respectively). (D) Box and
whisker plot describing average colony size (arbitrary units) in wild-type, tsc2Δ, ypa1D212G, and tsc2Δypa1-D212G mutants at day 5. Lower case letters represent
significant differences (if any) among the groups.
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Figure 3-9: tsc1∆ypa1-V208D and tsc2∆ypa1-V208D double mutants do not exhibit
reduced colony growth relative to the respective single mutants. (A) Heat map
describing average colony size (arbitrary units) in wild-type, tsc1Δ, ypa1-V208D, and
tsc1Δypa1-V208D mutants over five days (n = 11, 12, 12, and 11, respectively). (B)
Box and whisker plot describing average colony size (arbitrary units) in wild-type,
tsc1Δ, ypa1-V208D, and tsc1Δypa1-V208D mutants at day 5. (C) Heat map describing
average colony size (arbitrary units) in wild-type, tsc2Δ, ypa1-V208D, and tsc2Δypa1V208D mutants over five days (n = 12, 12, 10, and 11, respectively). (D) Box and
whisker plot describing average colony size (arbitrary units) in wild-type, tsc2Δ, ypa1V208D, and tsc2Δypa1-V208D mutants at day 5. Lower case letters represent significant
differences (if any) among the groups.
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Figure 3-10: tsc1∆fft3∆791-872 and tsc2∆fft3∆791-872 double mutants do not
exhibit reduced colony growth relative to the respective single mutants. (A) Heat
map describing average colony size (arbitrary units) in wild-type, tsc1Δ, fft3∆791-872
and tsc1Δfft3∆791-872 mutants over five days (n = 12, 12, 12, and 11, respectively).
(B) Box and whisker plot describing average colony size (arbitrary units) in wild-type,
tsc1Δ, fft3∆791-872, and tsc1Δfft3∆791-872 mutants at day 5. (C) Heat map describing
average colony size (arbitrary units) in wild-type, tsc2Δ, fft3∆791-872, and
tsc2Δfft3∆791-872 mutants over five days (n = 12, for all groups). (D) Box and whisker
plot describing average colony size (arbitrary units) in wild-type, tsc2Δ, fft3∆791-872,
and tsc2Δfft3∆791-872 mutants at day 5. Lower case letters represent significant
differences (if any) among the groups.
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Figure 3-11: tsc1∆fft3-K418R and tsc2∆fft3-K418R double mutants demonstrate
reduced colony growth relative to the respective single mutants. (A) Heat map
describing average colony size (arbitrary units) in wild-type, tsc1Δ, fft3-K418R, and
tsc1Δfft3-K418R mutants over five days (n = 12, 11, 12, and 11, respectively). (B) Box
and whisker plot describing average colony size (arbitrary units) in wild-type, tsc1Δ,
fft3-K418R, and tsc1Δfft3-K418R mutants at day 5. (C) Heat map describing average
colony size (arbitrary units) in wild-type, tsc2Δ, fft3-K418R, and tsc2Δfft3-K418R
mutants over five days (n = 12, 11, 12, and 12, respectively). (D) Box and whisker plot
describing average colony size (arbitrary units) in wild-type, tsc2Δ, fft3-K418R, and
tsc2Δfft3-K418R mutants at day 5. Lower case letters represent significant differences
(if any) among the groups.
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Figure 3-12: Clustal Omega alignment of human TSC2 and fission yeast Tsc2p.
Colored bars indicate domains of the human TSC2 protein that are conserved in S.
pombe Tsc2p. Pink labelled boxes indicate fission yeast Tsc2p mutations that are
orthologous to the corresponding disease-causing human TSC2 alleles. Sp,
Schizosaccharomyces pombe; Hs, Homo sapiens.
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and tsc2-R1296P fft3∆ double mutants were highly comparable to those of the tsc2∆ypa1∆
and tsc2∆fft3∆ double mutants (Figure 3-13 E, F). Thus, the observed interactions between
tsc2 and ypa1 or fft3 are indeed allele specific. This demonstrates that the loss of fft3 or
ypa1 activity is not necessarily detrimental to growth in all cells exhibiting deficiencies in
hamartin or tuberin function. Instead, the results imply that the genetic interactions depend
on the subtleties of Tsc1p/Tsc2p molecular function in an allele specific manner (see
Discussion).

3.5 Genotyping the mouse embryonic cell lines
The validated interactors from the initial screen in S. pombe have clear orthologs in
organisms ranging from yeast to humans. Thus, Ppp2r4 (ortholog of ypa1) and Smarcad1
(ortholog of fft3) were tested to see if the negative interactions were conserved in more
developmentally complex eukaryotes. To this end, Tsc2+/+p53-/- and Tsc2-/-p53-/- mouse
embryonic fibroblasts (MEFs) were obtained from Dr. DJ Kwiatkowski (Onda et al., 1999).
After the initial thawing process, the P118 (Tsc2+/+p53-/-) and P119 (Tsc2-/-p53-/-)
MEFs were sub-cultured twice before genotyping. Cells show typical fibroblastic
morphology (Figure 3-14 A, B) as reported earlier (Onda et al., 1999). For each type of
cells, gDNA was isolated and two simultaneous PCR reactions were performed using one
of either H163 (within exon 3 of Tsc2) or H164 primers (within the neomycin cassette
insert) in combination with the H162 primer (within exon 3 of Tsc2). Results show an
expected 198 base pairs (bp) PCR amplificon for the P118 MEFs (PCR product of
H163/H162), with no PCR product from H164/H162 (Figure 3-14 C). In contrast, there
was a H164/H162-96 bp PCR product amplified for the P119 MEFs, with no PCR product
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Figure 3-13: tsc2-R1296P ypa1∆ and tsc2-R1296P fft3∆ double mutants
demonstrate reduced colony growth relative to the respective single mutants. (A)
Heat map describing average colony size (arbitrary units) in wild-type, tsc2-R1296P,
ypa1∆, and tsc2-R1296P ypa1∆ mutants over five days (n = 8, 8, 8, and 6, respectively).
(B) Box and whisker plot describing average colony size (arbitrary units) in wild-type,
tsc2-R1296P, ypa1∆, and tsc2-R1296P ypa1∆ mutants at day 5. (C) Heat map
describing average colony size (arbitrary units) in wild-type, tsc2-R1296P, fft3∆, and
tsc2-R1296P fft3∆ mutants over five days (n = 10, for all groups). (D) Box and whisker
plot describing average colony size (arbitrary units) in wild-type, tsc2-R1296P, fft3∆,
and tsc2-R1296P fft3∆ mutants at day 5. (E) tsc2-R1296P ypa1∆ and tsc2∆ypa1∆
double mutants suffer from similar growth perturbations. (F) tsc2-R1296P fft3∆ and
tsc2∆fft3∆ double mutants exhibit similar growth impediment. Lower case letters
represent significant differences (if any) among the groups.
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Figure 3-14: Genotyping of the P118 and P119 MEF cell lines. (A) Microscopic
view of the P118 MEFs at passage 2, objective 20X, scale bar – 100 µm (light
microscopy). (B) Microscopic view of the P119 MEFs at passage 3, objective 20X,
scale bar – 100 µm (light microscopy). (C) The indicated primers (combination of
H162, H163, and H164) were used to PCR amplify genomic DNA from P118 and P119
cells. The resulting amplicons were run on a 1.7% agarose gel to confirm the
presence/absence of the neomycin cassette.
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from H163/H162 (Figure 3-14 C). The data confirmed that exon 3 of the Tsc2 gene is
disrupted in the P119 cells, and thus induced a loss of function mutation. Hence, the P119
MEFs provided a powerful tool for examining the synthetic interactions (identified in
fission yeast) in more developmentally complex eukaryotes.

3.6 Conservation of negative interactions in mouse embryonic fibroblasts
The validated interactors from the initial screen in S. pombe have clear orthologs in
developmentally complex eukaryotes, including mice and humans. Thus, Ppp2r4 (ortholog
of ypa1) and Smarcad1 (ortholog of fft3) were tested to see if the negative interactions were
conserved in the MEFs. Both P118 and P119 cells were transfected for 48 hours with 10
µM siRNAs. Treatments with scrambled siRNA had no effects on the mRNA expressions
of Smarcad1 and Ppp2r4 compared to the untreated samples. However, siRNAs
specifically targeting the mRNA of Smarcad1 or Ppp2r4 greatly abolished their respective
gene expressions (Figure 3-15).
Upon validation of siRNA-mediated knockdowns, cell viability was assayed to
determine synthetic interactions between Tsc2 and Ppp2r4 or Smarcad1. CellTiter-Glo
assays were utilized to monitor the number of viable cells based on the presence of ATP.
The reagent from the assay generated stable luminescent signals which were read through
a luminometer to approximate cell viability. The wild-type P118 and Tsc2-deficient P119
cells were transfected with either Ppp2r4 or Smarcad1 siRNAs. Results showed that both
Ppp2r4 and Smarcad1 siRNA treatments had no effects on cell viability of the P118 MEFs
(p > 0.05 for all pairwise comparisons with control group; Figure 3-16 A). Interestingly,
the Ppp2r4 siRNA-mediated knockdown in the Tsc2-deficient P119 MEFs demonstrated a
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significant reduction in the cell viability (~ 26% reduction, p = 0.01 for the pairwise
comparison with control group; Figure 3-16 B). This supports the hypothesis that negative
interaction between tsc2 and ypa1 witnessed in fission yeast may indeed be conserved in
mammals. Smarcad1, however, did not show a similar trend of negative interaction with
Tsc2 (p = 0.22 for pairwise comparison with control group; Figure 3-16 B).
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Figure 3-15: siRNA knockdown at 48 hours. (A) Smarcad1 and Ppp2r4 gene
expression in P118 cells is abolished upon siRNA treatments (lane 6 of each image).
(B) Smarcad1 and Ppp2r4 gene expression in P119 cells is abolished upon siRNA
treatments (lane 6 of each image). The housekeeping gene, Gapdh was used as a
control. U = untreated cells, Scr = negative control siRNA targeting no known mouse
genes, siRNA = corresponding siRNA used to knockdown gene of interest.
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Figure 3-16: Cell viability of MEFs 48 hours following siRNA treatment. (A)
Relative cell viability of P118 cells treated with a scrambled siRNA control or siRNAs
targeting Ppp2r4, or Smarcad1 (n = 3, for all groups). (B) Relative cell viability of
P119 cells treated with a scrambled siRNA control or siRNAs targeting Ppp2r4, or
Smarcad1 (n = 3, for all groups). Statistical analyses were performed using the
Friedman test in GraphPad Prism v7.0.2. **p = 0.01; n.s. denotes a statistically
insignificant difference.
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CHAPTER IV: DISCUSSION

The primary objective of this study was to explore the genetic interaction network
underlying tuberous sclerosis complex. This was done in part to elucidate the mechanism
of the TSC pathogenesis; but, also to identify prospective drug targets for novel therapeutic
strategies. The study looked to utilize large-scale genetic buffering relationships
discovered in fission yeast to reveal negative interactors of both tsc1 and tsc2. In addition,
RNAi knockdowns in mammalian cells were used to further assess any promising
candidates screened through the fission yeast genetic interactions.

4.1 Overview of the fission yeast genetic interactome
Genetic interactions are vital in the translation of genotypic information to phenotypic
consequences. These networks are known to be important in understanding complex
human diseases and may play a role in the mystery of ‘missing heritability’ (Horn et al.,
2011; Zuk et al., 2012). Analyses in model systems support the notion that genetic
interactions between alleles can inflate variation and phenotypic outcomes (Horn et al.,
2011). Unlike protein-protein interactions, genetic interactions are not limited to physical
association between their respective encoded proteins (Ryan et al., 2012). In fact, only ~1%
of the genetic interactions overlap with corresponding protein-protein interactions (Boone
et al., 2007; Tong et al., 2004). Instead, genetic interactomes provide invaluable
information with respect to functional attributes of genes and often reveal the role of gene
products involved in functionally related pathways (Boone et al., 2007; Ryan et al., 2012).
Most genes exhibit few genetic interactions, while a few genes (‘hubs’) are highly
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connected in the interaction map and are more likely to be functionally important (Tong et
al., 2004).
The budding yeast S. cerevisiae was first analyzed to generate large-scale genetic
interaction networks (Costanzo et al., 2010). However, such analysis in the distantly related
S. pombe was limited to small scale investigations of specific pathways and cellular
processes (Roguev et al., 2007; Roguev et al., 2008). Nonetheless, a quantitative and
genome-wide S. pombe genetic interactome was recently mapped, encompassing ~50% of
the genome with ~1.6 million generated digenic interactions (Ryan et al., 2012). In
addition, the group annotated numerous functions to previously uncharacterized genes. The
generation of this powerful dataset provided an opportunity to examine prospective
synthetic interactions concerning tuberous sclerosis complex.

4.2 Characterization of the validated negative interactors
Fission yeast Tsc1p and Tsc2p act in pathways akin to their respective homologs in humans
(TSC1 and TSC2). This study aimed to exploit recent work (Housden et al., 2015; Ryan et
al., 2012) to identify negative interactor genes of both tsc1 and tsc2 in fission yeast. The
colony growth assays validated ypa1 and fft3, but not cdk11, as negative interactors of tsc1
and tsc2 (Figure 3-2 to 3-4). The data were in accordance with the prediction that complete
gene deletions of ypa1 and fft3 in tsc1∆ and tsc2∆ backgrounds would result in severe
reduction of colony growth size.
Fission yeast ypa1 encodes the protein – phosphotyrosyl phosphatase activator
(PTPA, also known as Ypa1p). Little is known about fission yeast PTPA, except that it
regulates the activity of serine/threonine protein phosphatase 2A (PP2A) (Goyal and
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Simanis, 2012). Likewise, the budding yeast PTPA (encoded by rrd1) regulate the catalytic
activity of PP2A, which is a known associate of the TOR pathway (Poschmann et al., 2011;
Van Hoof et al., 2000; Zheng and Jiang, 2005). Mutants bearing rrd1Δ have several
morphological defects including irregular progression through G1/S transition of the cell
cycle (Jordens et al., 2006; Van Hoof et al., 2001). Interestingly, researchers have
discovered that DNA-dependent protein kinase (DNA-PK) activation by PP2A is required
for the repair of double stranded breaks (DSBs) through non-homologous end joining
(NHEJ) (Li et al., 2013) and the process is known to occur primarily in the G1 phase (Chen
et al., 2011). Additionally, PTPA association with RNA polymerase II (RNAPII) is crucial
in the regulation of stress-responsive genes (Poschmann et al., 2011). In rrd1Δ mutants,
transcriptional control may be lost due to RNAPII disassociation from the coding
sequences (Sen et al., 2014). Taken together, budding yeast PTPA may act to regulate the
TOR pathways and the NHEJ pathway of DNA repair indirectly through PP2A activity,
and work directly to activate RNAPII mediated transcription of stress-responsive genes.
Whether the S. pombe PTPA participates in DNA damage repair and the regulation of the
cell cycle in similar ways requires more comprehensive analyses.
The Fft3 protein is a Swi/Snf2 family ATP-dependent chromatin remodeler that is
greatly conserved across many eukaryotes (Steglich et al., 2015). Previous work has
demonstrated that Fft3p is essential in maintaining the heterochromatin structure of the
centromeric and sub-telomeric regions and plays a role in the regulation of the overall
nuclear organization (Steglich et al., 2015; Strålfors et al., 2011). In S. pombe, fft3∆ results
in euchromatin formation leading to incorrect histone modifications and mis-regulation of
gene expression (Strålfors et al., 2011). Thus, Fft3p may be crucial in key cellular processes
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such as transcription, DNA repair and DNA replication (Steglich et al., 2015).
Interestingly, Fft3p orthologs – Fun30 in S. cerevisiae and SMARCAD1 in humans, are
known to aid in DNA end resection of DSBs via G2 cell cycle homologous recombination
(HR) (Chen et al., 2012; Costelloe et al., 2012; Eapen et al., 2012). Inability to successfully
repair DSBs compromises genome integrity and leads to prolonged G1/G2 checkpoint
arrest which often results in apoptosis (Massagué, 2004). Fun30 can increase the rate of
the 5’-to-3’ DNA resection and deactivate the G2/M DNA damage checkpoint arrest
(Eapen et al., 2012). This is done at the chromatin level, where Fun30 (as well as the human
homolog SMARCAD1) can relax the tight histone-DNA interactions in nucleosomes
adjacent to DSBs (Chen et al., 2012; Costelloe et al., 2012). In fission yeast, however, the
precise mechanism of the Fft3p role in the DNA damage repair has not been explored.
As discussed earlier, genetic interactions rarely implicate physically associated
gene products (Tong et al., 2004). Furthermore, only a small subset of strong negative
interactions amount to interactions in ‘within-pathway’ complexes (Costanzo et al., 2011).
In S. cerevisiae, most synthetic lethal interactions, albeit rare, occur between genes with
similar cellular functions (Tong et al., 2004). Fission yeast hamartin-tuberin heterodimeric
complex have been shown to play a role in the regulation of nutrient uptake, cellular growth
and stress response (Aspuria et al., 2007; Mak and Yeung, 2004); and the role of Ypa1p,
Fft3p and their homologs has been discussed above. Thus, it is highly likely that the strong
negative genetic interactions exhibited among ypa1, fft3, and tsc1/2 do not correspond to
physical protein-protein interactions. Instead, the results in this study suggest that the genes
participate in ‘between-pathway’ genetic interactions. These interactions often occur
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among functionally related genes in complementary biological pathways (Boone et al.,
2017).
In S. pombe, the role of Ypa1p and Fft3p suggests that cellular processes such as
transcription and DNA repair may contribute to the Tsc1p-Tsc2p controlled TOR pathways
which regulates cellular growth, proliferation and stress-response. Interestingly, Ypa1p is
known to regulate the activity of PP2A (Goyal and Simanis, 2012) and its budding yeast
ortholog is associated with the TOR pathways (Poschmann et al., 2011; Van Hoof et al.,
2000; Zheng and Jiang, 2005). Thus, the fission yeast PTPA (Ypa1p) may yet be implicated
in the TOR pathways and the functional complementarity among the protein products of
the genes (ypa1, fft3, tsc1, and tsc2) could provide an explanation for the strong negative
interactions validated in this study.
Interestingly, however, ypa1 and fft3 did not demonstrate any synthetic
interactions between the genes (data not shown). This finding supports the notion that
Ypa1p and Fft3p are involved in different pathways that can impinge on shared function
affecting cellular growth. Hence, although negative genetic interactions are frequent
between genes within the same cellular pathway or pathways that are closely linked
(Baryshnikova et al., 2010), it may not be a requirement. In fact, ‘hub’ genes can interact
with numerous genes making them essential to a wide range of cellular processes (Boone
et al., 2007). Therefore, these genes are crucial in modulating phenotypic variation and
complexity. Whether tsc1 and tsc2 can be considered as ‘hub’ genes remain to be
determined. Here, the findings suggest that the fission yeast cells with tumor-like molecular
context (loss of functional tsc1 and tsc2) can be selectively targeted to inhibit growth.
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Hence, Ypa1p and Fft3p provide promising candidates for further investigation and are
prospective drug targets in TSC therapeutics.
4.3 Applying the concept of synthetic chemical-genetic interactions
A traditional strategy for anticancer drug discovery is to assay inhibitory compounds for
their ability to selectively target cells that mimic the molecular alterations of tumor cells
(Hartwell et al., 1997). Using the digenic negative interaction dataset, specific
pharmacological inhibitors can be screened for lethality emulating novel drug-gene
synthetic interactions (Beijersbergen et al., 2017; Boone et al., 2007; Kaelin, 2005; Nijman,
2011). Inhibition of the catalytic domains in Ypa1p and Fft3p by chemical treatments in
combination with tsc1 or tsc2 loss of function mutations, therefore, should result in cellular
growth defects. In principle, this may allow for selective targeting of tumor cells (lacking
functional TSC1 and TSC2) using synthetic lethal chemical-genetic interactions (Boone et
al., 2007). Thus, it was important to identify sites that may be amenable to chemical
inhibition within the fission yeast Ypa1p and Fft3p.
The study first examined the highly conserved PPIase domain of the Ypa1p
(PTPA). The PTPA PPIase domain is well conserved across eukaryotes including the
budding yeast (Chao et al., 2006, Jordens et al., 2006; Leulliot et al., 2006). Proteomic
analyses have shown that PTPA mutations in budding yeast aspartate213 and valine209 sites
within the catalytic core compromised binding with PP2A (Chao et al., 2006; Leulliot et
al., 2006). Also, mutations in these sites resulted in the loss of the PTPA phosphatase
activity and abolished ATP-dependent activation of PP2A (Guo et al., 2014). Their
orthologous S. pombe strains – ypa1-D212G and ypa-V208D, however, did not seem to
suffer from a similar loss of function, as the double mutants with tsc1∆ and tsc2∆ did not
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exhibit expected growth perturbations (Figures 3-8 and 3-9). These results suggest one of
two possibilities. First, that unlike mutations in the S. cerevisiae PTPA, these subtle
missense mutations do not cause significant conformational changes in the fission yeast
PTPA and abolish the PPIase activity, or second, that the observed synthetic growth defect
results from the loss-of-function of a PPIase independent activity. Interestingly, S.
cerevisiae mutants bearing complete deletion of the catalytic PPIase domain have been
shown to drastically impair the activation of PP2A (Jordens et al., 2006). The work in my
study aimed to reciprocate this deletion in S. pombe, but was unable to generate any viable
strain (data not shown).
In contrast, the ATPase dead fft3-K418R mutants demonstrated synthetic growth
defects with both tsc1 and tsc2 as predicted (Figure 3-11). In fission yeast, the ATPase
activity of Fft3p has been shown to maintain subtelomeric and centromeric
heterochromatin structures (Steglich et al., 2015; Strålfors et al., 2011). Moreover, the
ATPase domain is important to the function of many other SWI/SNF chromatin remodelers
(Hargreaves and Crabtree, 2011), and is highly conserved across eukaryotes (Figure 3-7).
Previous studies in S. cerevisiae showed that ATPase dead Fun30 mutants suffered G2 cell
cycle arrest due to unsuccessful 5’ to 3’ DNA end resection of DSBs (Chen et al., 2012;
Eapen et al., 2012). Likewise, siRNA knockdowns of SMARCAD1 (Fft3p and Fun30
homolog in humans) resulted in accumulation of cells with DNA damage and impaired
DNA repair mechanisms (Costelloe et al., 2012). Furthermore, in budding yeasts, the
Fun30 helicase domain is thought to be important in the remodeling of nucleosomes and
efficient DNA end resection (Awad et al., 2010; Chen et al., 2012). However, the helicasedeleted fission yeast mutants (fft3∆791-872) did not display synthetic growth defects with
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either tsc1 or tsc2 (Figure 3-10). Here, the results suggest that the loss of the ATPase
activity of Fft3p through a site-directed mutation (K418R) is primarily responsible for the
observed negative interaction. Thus, the data suggest a prospective site of pharmacological
inhibition within Fft3p that might recapitulate the negative interaction between fft3 and
tsc1/tsc2.

4.4 Investigation of disease-causing clinical mutations in S. pombe
Although mutations in TSC1 and TSC2 can be inherited as autosomal dominant traits (in
familial cases with at least one affected parent), most cases of TSC are sporadic (~65%
without an affected parent) (Narayanan, 2003). TSC2 mutations are significantly
overrepresented among sporadic cases of the disease (Jones et al., 1999; Napolioni and
Curatolo, 2008). Furthermore, clinical phenotypes arising from patients with TSC2
mutations are more severe (Franz and Weiss, 2012; Mak and Yeung, 2004; Neuman and
Henske, 2011). Thus, the study sought to investigate clinical TSC2 mutations. Six S. pombe
strains with tsc2 alleles bearing orthologous TSC2 missense mutations were examined, to
test for synthetic interactions with the validated negative interactors – ypa1 and fft3 (Figure
3-12). The data indicated that only the tsc2-R1296P allele exhibits synthetic growth defects
with both ypa1∆ and fft3∆, as previously predicted (Figure 3-13).
The tuberin GAP domain is well conserved in S. pombe with ~ 45% amino acid
sequence similarity (Neuman and Henske, 2011; Serfontein et al., 2011). Three diseasecausing missense mutations within this domain are frequent within TSC patients –
N1643K, N1651S, and P1675L (Jones et al., 1999). Their corresponding orthologous
mutations in S. pombe (N1191K, N1199S, and P1223L) have been shown to limit nutrient
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uptake and arginine biosynthesis underlining a unique function of the fission yeast Tsc2p
GAP domain (van Slegtenhorst et al., 2004). Here, the absence of negative genetic
interactions involving these mutants in ypa1∆ and fft3∆ backgrounds suggest that these
mutations do not cause synthetic growth defects that were witnessed when tsc2 was fully
deleted. Likewise, two other mutant strains outside the Tsc2p GAP domain (G296E and
R927W) were tested and exhibited normal colony growth. The results, therefore, indicate
that either these missense mutations in fission yeast do not attribute to loss of Tsc2p
functions contrary to their orthologous mutations in clinical TSC cases or, that the negative
interactions between tsc2 and ypa1 or fft3 is conditional on loss of tuberin completely.
The arginine1743 and arginine1745 sites exist outside the GAP domain near the Cterminus of TSC2 (Jones et al., 1999). Surprisingly, mutations in these sites (R1743P and
R1745Q) abolish the GAP activity of TSC2 and result in the inability to phosphorylate
downstream p70S6K1 (Li et al., 2004). Patients bearing these mutations therefore suffer
from the TSC pathology due to an indirect mis-regulation of the tuberin GAP activity (Li
et al., 2004). In fission yeast, the patient-derived arginine sites are conserved as R1296 and
R1298 sites. Although, the orthologous tsc2-R1298Q strain was not included in this study,
the synthetic growth defects exhibited by S. pombe strains bearing the tsc2-R1296P allele
indicate that this specific site may indeed be important for functional Tsc2p activity. Thus,
negative interactions between clinically orthologous mutations, and ypa1 or fft3 do not
appear to be conditional on the complete loss of tuberin. Additionally, the synthetic genetic
interactions between tsc2-R1296P allele with both ypa1 and fft3 may allude to a broader
conservation of these negative interactions across TSC patients and warrants a more
comprehensive analysis of the diverse TSC1 and TSC2 mutations.
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4.5 Conservation of synthetic interactions
Previous work has focused on the conservation of genetic interactions across the distantly
related eukaryotes, S. pombe and S. cerevisiae (Dixon et al., 2008; Roguev et al., 2008).
The two unicellular yeasts share 30% of the genetic interactome (Dixon et al., 2008;
Roguev et al., 2008). Given the ~ 400 million years of evolutionary separation between the
species, this rate of conservation is extensive. Moreover, a large-scale RNAi screen in the
nematode Caenorhabditis elegans identified a set of ‘hub’ genes that share numerous
genetic interactions (Lehner et al., 2006). These genes encode highly conserved chromatin
regulators and their genetic interactions are conserved across species (Lehner et al., 2006).
Genetic interactions between genes within the same pathway tend to be conserved at a
higher rate (~ 45%) than those belonging to different processes (~15%) (Ryan et al., 2012).
The negative interactions examined in this study (among ypa1, fft3, tsc1, and tsc2) are
presumably involved in ‘between-pathway’ genetic interactions; and such interactions are
less frequently conserved, at a rate of ~ 15% (compared to the ~35% conservation rate for
‘within-pathway’ negative interactions) (Ryan et al., 2012).
Nonetheless, a recent breakthrough using CRISPR-based Tsc2-knockout
Drosophila spp. cell lines and Tsc2-/- MEFs demonstrated that TSC-specific synthetic
interactions may indeed be conserved in higher eukaryotes (Housden et al., 2015). Further
assessment of these interactions in these Tsc2-deficient MEFs was essential to evaluating
prospective drug targets identified in this study. siRNA knockdowns of the ypa1 and fft3
homologs – Ppp2r4 and Smarcad1, in the Tsc2-deficient mammalian cells abolished their
respective gene expression (Figure 3-15). However, only the Ppp2r4 knockdown resulted
in decreased cellular viability in Tsc2-/- MEFs compared to the wild type cells (Figure 362

16). In contrast, the Smarcad1 knockdown had no effects on the survivability of the Tsc2deficient MEFs. Altogether, this study provide evidence that, while some genetic buffering
relationships may be conserved across species, others are not. This phenomenon may be
explained by the possibility of functional ‘repurposing’ as a result of evolutionary
divergence and associations of genetic interactions, in addition to the widespread
conservation among species (Frost et al., 2012). Nonetheless, the results here suggest that
the Ppp2r4 gene product in humans, PPP2R4, might represent an ideal drug target and,
thus, may contribute to novel therapeutic strategies to combat the TSC pathology.

4.6 Implications, challenges and future directions
The understanding of human biology and diseases goes beyond the functions of single
genes in isolation (Hartman IV et al., 2001). Complex genetic interaction networks are
involved in a multitude of phenotypic consequences including genetic disorders and
disease. Genome-wide studies of genetic interactions have led to construction of largescale interactomes that provide an opportunity to visualize such complexity (Boone et al.,
2007). In particular, synthetic relationships have played a vital role in the understanding of
disease mechanisms, drug discovery and novel therapeutic strategies (Nijman, 2011). This
study sought to utilize the recently developed S. pombe genetic interactome to elucidate
the molecular pathology of tuberous sclerosis complex and to identify novel diseasespecific drug targets.
Although the efforts of this study have led to the discovery of a prospective TSCspecific drug target PPP2R4, limitations remain. First, the isogenic S. pombe strains and
MEFs used in this study present an inevitable quandary. They are invaluable tools in
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evaluating the fitness of single mutants with those of the double mutants and help elucidate
gene buffering relationships (Hartman IV et al., 2001). However, the isogenic background
of these strains and cell lines often ignores background differences and simplifies the
complexity within these model systems and thus, limit understanding at a deeper level.
Also, RNAi tools used in this study offer incomplete transfection, partial gene
knockdowns, and can have frequent off-target effects leading to false negatives and
positives (Housden et al., 2015). Therefore, the conservation of the synthetic interactions
across species requires a more complete examination. Additionally, this study solely
focused on these interactions in cells mimicking loss-of-function mutations in TSC2 (Tsc2/-

MEFs). Thus, a comprehensive analysis should look to include investigation in cellular

contexts bearing TSC1 loss-of-function mutations. Interestingly, Housden et al. (2015)
developed TSC1 and TSC2 mutant lines in Drosophila spp. and thus, present an opportunity
for in-depth examination in a different model system.
Second, the characterization of the negative interactors was limited in the context
of this work. Fission yeast ypa1 is poorly understood (Goyal and Simanis, 2012) and thus,
requires extensive cellular and molecular analysis to determine the exact role of the PTPA
gene product (also known as Ypa1p). In contrast, fft3 is relatively well studied in S. pombe,
with roles in heterochromatin preservation, transcription, epigenetic inheritance and DNA
replication (Steglich et al., 2015; Strålfors et al., 2011; Taneja et al., 2017); however, the
detailed machineries of the Fft3p is yet to be explored. Altogether, a comprehensive study
of these interactors and their orthologs in humans may help generate useful insights into
the mechanisms of their corresponding gene products, and such information combined with
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the genetic interaction data may help provide a greater understanding of the tuberous
sclerosis pathogenesis.
Third, a widespread phenomenon known as NGE can drastically affect large-scale
genetic interaction data sets (Ben-Shitrit et al., 2012). NGEs can arise from the effects of
gene deletions on the expression of adjacent genes along the genome (Atias et al., 2015).
While the mechanism of these effects remains unknown, it is possible that the deletion of
a given locus alters chromatin structure and/or the regulatory characteristics of adjacent
loci (Baryshnikova and Andrews, 2012). Recent analysis of the S. cerevisiae genetic
interactome has revealed that ~ 10% of the scored genetic interactions are affected by NGE
and the corresponding data sets may be erroneous (Atias et al., 2015). Efforts were made
to investigate NGE effects on the synthetic interactions observed in this study (Figures 35 and 3-6). Although the data strongly suggest absence of any NGE effects, the analysis is
not nearly comprehensive enough. Only two adjacent gene deletions were tested for NGE
effects on each negative interactor (ypa1 and fft3). Thus, the need to increase the number
of genes included in the NGE studies is apparent. Future annotations of genetic interactions
may look to utilize recently developed algorithms (Atias et al., 2015; Ben-Shitrit et al.,
2012), that are capable of not only detecting these interactions, but also finding ways to
correct them.
Lastly, although the S. pombe genetic interaction data sets are considered largescale and encompasses ~ 50% of the genome, it is not entirely complete and suffers from
limitations. In fact, the more established S. cerevisiae genetic interactome corresponds to
only ~ 2% of all genetic interactions within a typical mammalian cells (Ryan et al., 2012).
Thus, the translation of genetic interaction studies from unicellular eukaryotes such as
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fission yeast to higher eukaryotes presents difficulty. The presence of multiple tissues,
numerous cell types and intricate signaling networks in higher eukaryotes can further add
to the complexity. This obscures the evaluation of any prospective candidates for TSCspecific therapeutic intervention identified through the fission yeast genetic interactome.
More complete and diverse analyses are thus required in multiple TSC disease-models in
addition to the Tsc2-/- MEFs used in this study. Interestingly, patient derived TSC2deficient lymphangioleiomyomatosis (LAM) cells have proven a useful model in studying
tumorigenesis (Li et al., 2014). Furthermore, recent advances in platforms such as shRNA
knockdown and CRISPR/Cas9-mediated gene knockouts have also made it possible to
perform synthetic screens for numerous pairs of genes in a large population of cells
(Beijersbergen et al., 2016). Thus, future studies should aim to utilize these technological
advances to generate a more comprehensive mammalian genetic interactome from various
tissues and cell types.
In conclusion, by combining the genome-wide fission yeast interactome with TSCspecific genetic networks, this study has helped to shed insights into the molecular
pathology of tuberous sclerosis complex. In TSC patients, loss of a functional TSC1-TSC2
heterodimer causes over activation of mTORC1, resulting in increased metabolic and
oxidative cellular stresses (Beijersbergen et al., 2016). In tumor cells, the rate of cellular
metabolism increases greatly as the requirement of various cellular processes is enhanced
(Kroemer and Pouyssegur 2008). Inhibiting key components in the metabolic processes
can severely impair tumor cells while leaving normal cells relatively unaffected, as the
tumor-specific cells become highly prone to growth arrest and subsequent cell death
(Kroemer and Pouyssegur 2008). Hence, targeted inhibition of PPP2R4 might represent an
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“Achilles’ heel” of the TSC-specific tumors and represents a novel drug target for
therapeutic intervention. The robustness of this investigation is demonstrated by the
discovery of a disease-specific drug target utilizing genetic interaction biology
(Beijersbergen et al., 2016), suggesting that such data sets are invaluable in understanding
complex human disorders and may aid in future disease-associated inquiries.
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